- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Interventions
- Observational
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 16,130
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
- Interventions
- AZD6750, rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Scleroderma, Systemic
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Interventions
- ECI830, ribociclib, fulvestrant
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more
- Conditions
- Breast Cancer
- Interventions
- DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2016
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Rochester, Minnesota + 1 more
- Conditions
- Breast Cancer
- Interventions
- 49-channel optical spectrometer
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Neoplasms
- Interventions
- Doxorubicin, Cyclophosphamide, Docetaxel, Herceptin, Carboplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 3,222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2014
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Metastatic Breast Cancer
- Interventions
- Enobosarm, Exemestane
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
- Conditions
- Breast Cancer, Hot Flashes
- Interventions
- pregabalin, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 209
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 135 more
- Conditions
- Eczema, Atopic Dermatitis
- Interventions
- Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
- Device
- Lead sponsor
- Frankel, Amylynne, M.D.
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Surgery
- Interventions
- IONM procedure
- Procedure
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane), Sorafenib (Nexavar)
- Drug
- Lead sponsor
- Veeda Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- Exercise Training, Chemo only
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- LY3361237, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Clearwater, Florida • Tampa, Florida + 6 more
- Conditions
- Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
- Interventions
- Radezolid, Linezolid
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 19
- States / cities
- Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Interventions
- Team-Based Connected Health (TCH)
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Endometriosis
- Interventions
- simvastatin 10mg, Bazedoxifene 20/Estrogens,Con 0.45Mg Tb
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Herpes Simplex, HIV Infections
- Interventions
- Vidarabine, Acyclovir, Foscarnet sodium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more
- Conditions
- Menkes Disease
- Interventions
- Droxidopa Oral Product, Placebo Control
- Drug · Other
- Lead sponsor
- Stephen G. Kaler
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 103
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Cancer Female, Neoplasms
- Interventions
- contrast-enhanced mammography
- Device
- Lead sponsor
- Wendie Berg
- Other
- Eligibility
- 30 Years to 79 Years · Female only
- Enrollment
- 1,600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 6
- States / cities
- Bethel Park, Pennsylvania • Cranberry Township, Pennsylvania • Monroeville, Pennsylvania + 2 more
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- PI3K inhibitor BYL719, letrozole, laboratory biomarker analysis, pharmacological studies
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
- Interventions
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Drug · Other
- Lead sponsor
- Dan Zandberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sjögren's Disease
- Interventions
- DDY391, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Clearwater, Florida • Tampa, Florida • Chicago, Illinois + 7 more